Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
A 3D tumour model developed by scientists enables drug screening in metastases
Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
The efficacy of therapeutic antibodies is defined by their primary amino acid sequence. After discovery, antibody candidates often profit from protein engineering and sequence optimisation. Different technologies can improve the functional properties of antibodies as well as their biochemical and biophysical characteristics influencing manufacturing, process development, formulation, and other parameters of the final drug target product profile.
Biologicals have shown significant success for more complex diseases, whereas small molecule drugs have not been that effective. New biologicals are mostly highly purified proteins or antibodies, which require the development of technologies for the preparation of a large number of drug candidates with high purity and speed. A high throughput magnetic beads-based system is a game-changer for biologics discovery.
The 12th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.